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Open access under CC BY-NC-ND license.SUMMARYRAS proteins directly activate PI3-kinases. Mice bearing a germline mutation in the RAS binding domain of
the p110a subunit of PI3-kinse are resistant to the development of RAS-driven tumors. However, it is
unknown whether interaction of RAS with PI3-kinase is required in established tumors. The need for RAS
interactionwith p110a in themaintenance ofmutantKras-driven lung tumorswas explored using an inducible
mouse model. In established tumors, removal of the ability of p110a to interact with RAS causes long-term
tumor stasis and partial regression. This is a tumor cell-autonomous effect, which is improved significantly by
combinationwithMEK inhibition. Total removal of p110a expression or activity has comparable effects, albeit
with greater toxicities.INTRODUCTION
Activating point mutations in the genes encoding the RAS sub-
family of small GTP binding proteins drive the formation of a large
proportion of human tumors. RAS proteins control cell growth
through several direct effector enzyme families, the best studied
of which are RAF kinases, type I phosphoinositide (PI)3-kinases,
and RAL-guanine nucleotide exchange factors (RAL-GEFs)
(Downward, 2003; Pylayeva-Gupta et al., 2011). Of these,
BRAF and PIK3CA, the genes encoding BRAF and the p110a
PI3-kinase catalytic subunit, respectively, are frequently acti-
vated by somatic mutation in human cancer (Weir et al., 2004),
with overall mutation frequencies around 10% for each. PI3-
kinase activity is further implicated in carcinogenesis by theSignificance
Blocking the interaction of PI3-kinase p110awith RAS aswell a
shown to be beneficial in the treatment of established Krasmu
has similar effects on Krasmutant tumor regression to total rem
central importance in maintaining PI3-kinase signaling in RA
approach to targeting these tumors than total PI3-kinase en
another major RAS effector pathway, RAF/MEK/ERK, togeth
causes major tumor regression.
Canfrequent inactivation of the inositol lipid 30phosphatase PTEN
(Cully et al., 2006).
The importance of the interaction of mutant RAS with endog-
enous p110a in tumor development was established by the find-
ings thatmicewithmutations in the RAS binding domain (RBD) of
p110a were highly resistant to mutant Kras-induced lung cancer
formation and mutant Hras-induced skin cancer formation
(Gupta et al., 2007). However, it has been speculated that the
signaling pathway requirements for tumor cells to survive (tumor
maintenance) may be considerably relaxed relative to the
signaling pathway activity needed to convert a normal cell into
a tumor cell (tumor development) (Lim and Counter, 2005). As
tumor maintenance is more relevant than tumor initiation to the
treatment of preexisting human cancers, the question of whethers total loss of p110a or inhibition of its lipid kinase activity are
tant lung cancer. Because preventing RAS binding to p110a
oval of p110a, the interaction between RAS and p110a has
S-driven cancers. Blocking this could provide a less toxic
zymatic inhibition. Furthermore, simultaneous inhibition of
er with blockade of either p110a or all type I PI3-kinases,
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Figure 1. Expression of p110a-RBD Induces Tumor Regression in Early-Stage Tumors
(A) Schematic representation of experimental conditions.
(B) Representative images of 4-week-old and 16-week-old mouse lungs treated and untreated with tamoxifen (TX). Graph showing tumor number on the pleural
surface of lungs. Four-week-old group: Pik3caWT/flox n = 7mice, Pik3caRBD/flox n = 11; 16-week-old group: Pik3caWT/flox n = 9, Pik3caRBD/flox n = 12, Pik3caWT/- n =
10, Pik3caRBD/- n = 11 mice.
(C) Representative H&E-stained lung sections from 4-week-old and 16-week-old mice. Representation of tumor burden (tumor area as a percentage of total lung
area) in 4-week-old mice and in 16-week-old mice 12 weeks after tamoxifen treatment.
(legend continued on next page)
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RAS Binding to PI3-Kinase in Tumor Maintenanceblocking the interaction of RAS with p110a will affect the main-
tenance of an existing RAS mutant tumor is of considerable
importance.
Inhibition of PI3-kinase activity has been reported to have a
significant impact on RAS-induced tumors in some settings,
especially when combined with inhibition of the RAF/mitogen-
activated protein kinase extracellular signal-regulated kinase
kinase (MEK)/extracellular signal-regulatedkinase (ERK)pathway
(Engelman et al., 2008; Halilovic et al., 2010; She et al., 2010; Sos
et al., 2009). However, it has been unclear whether PI3-kinase
signaling is more important for RAS mutant tumors compared
to tumors with other oncogenic drivers or to normal cells. Also,
where such PI3-kinase dependency exists, it is not known
whether this is because of acute RAS-induced activation of PI3-
kinase through direct interaction with the RBD of p110 or more
indirect and long-termmechanisms, such as transcriptional upre-
gulation of ligands of growth factor receptor tyrosine kinases.
Here, we have set out to address the issue of the importance,
or otherwise, of the direct interaction of RASwith the RBD of PI3-
kinase p110a in the maintenance of RAS-induced tumors.
RESULTS
Removal of RAS Interaction with PI3-Kinase p110a in
Early-Stage Tumors Reduces Tumor Burden
In order to investigate the role played by the direct interaction of
p110a with RAS in tumor maintenance, we used a previously
generated mouse model in which the interaction of p110a with
RAS was disrupted by the introduction of two point mutations,
T208D and K227A, into the endogenous Pik3ca gene (Pik3caRBD)
(Gupta et al., 2007). Wild-type (Pik3caWT) and Pik3caRBD mice
were bred with mice containing a floxed Pik3ca allele (Zhao
et al., 2006) and amouse carrying a conditional Cre recombinase
(Cre-ERT2) allele targeted to the ubiquitously expressed Rosa26
locus. Finally, they were bred with KrasLA2 mice (Johnson et al.,
2001) so that they spontaneously developed lung adenocarci-
nomas (Figure 1A). By feeding these mice with a tamoxifen diet
for 2 weeks, we were able to efficiently remove the floxed Pik3ca
allele (Figure S1A available online), leaving only one Pik3caWT or
Pik3caRBD allele expressed in these mice.
Initially, we set out to determine the effect of removing the abil-
ity of endogenous p110a to interact with endogenous RAS on
RAS-driven tumors at the earliest possible stages, attempting
to mimic as closely as possible the constitutive Pik3caRBDmuta-
tion knockin reported previously (Gupta et al., 2007). In this we
were limited by the fact that tamoxifen treatment of Rosa26-
CreERT2 mice in utero or prior to weaning has been associated
with Cre recombinase-mediated genotoxicity (Schmidt-Suppr-
ian and Rajewsky, 2007). We therefore treated 4-week-old
mice with tamoxifen (Figure 1A), an age at which some small
tumors had already formed, thus switching the mice to express
Pik3caRBD alone (Pik3caRBD/). We could verify an efficient
removal of the floxed allele after the 2-week treatment not only
in the tumors, but also in several other tissues (Figure S1A).(D) Representation of average tumor size from the same group of mice mentione
(E) Quantification of TUNEL positive tumors in 16 weeks old Pik3caRBD/ and Pik
(F) Analysis of the proliferative state of Pik3caWT/ and Pik3caRBD/ tumors using
Error bars indicate mean ± SEM (significance using Student’s t test: **p < 0.01, *
CanThe number of tumors present on the surface of the lungs of
these mice was determined at 16 weeks of age. The number
of tumors in Pik3caRBD/ mice was strikingly reduced when
compared to their control counterparts, indicating that suppres-
sion of RAS interaction with p110a greatly impairs tumor growth
and maintenance at this stage (Figure 1B). We also observed a
decrease in tumor number in Pik3caRBD/ mice at the end of
the experiment when compared toPik3caRBD/floxmice at 4weeks
of age prior to the beginning of tamoxifen treatment, thus sug-
gesting tumor regression in Pik3caRBD/mice and not just slower
tumor development.
These results were confirmed by histopathological analyses
performed on these samples (Figures 1C, 1D, and S1B). Tumor
burden, number, and size were greatly reduced in Pik3caRBD/
tumors compared to the Pik3caWT/, Pik3caRBD/flox, or
Pik3caWT/flox tumors. We observed some decrease of the tumor
burden in Pik3caRBD/flox mice compared to Pik3caWT/flox mice
in the absence of tamoxifen treatment (see below). There was,
however, no difference in tumor burden in the heterozygous
Pik3caWT/flox mice without (WT/flox) and with (WT/) tamoxifen
treatment, suggesting that Pik3ca gene copy number does not
have a major effect on tumor growth at this stage.
We also determined tumor grade according to standard histo-
pathological characteristics (Jackson et al., 2005) and found no
differences in the existing tumors between Pik3caRBD/ mice
and Pik3caWT/mice (Figure S1C). Immunohistochemistry stain-
ing showed a decrease in phospho-ERK (p-ERK) and p-S6 in
Pik3caRBD/ tumors (Figure S1D). Furthermore, the levels of
cell proliferation and apoptosis were studied in the tumors of
these animals. As shown in Figure 1E, TUNEL staining revealed
an increase in the number of tumors displaying apoptosis in
Pik3caRBD/ animals when compared to the Pik3caWT/. The
proliferative rates in the tumors in the two backgrounds were
also different, as measured by phospho-histone H3 staining for
mitotic cells. We could see a higher number of cells stained in
thePik3caWT/ tumors than in thePik3caRBD/ tumors (Figure 1F),
so it is likely that the difference in the sizes of the tumors in the
wild-type and the PI3-kinase mutant backgrounds is at least in
part due to both elevated rates of cell death and decreased
proliferation in the absence of direct RAS binding to p110a.
Previous results in our lab using the constitutive knockin
Pik3caRBD mice had shown no differences in tumor formation
between wild-type (WT) and heterozygous Pik3caRBD/WT mice,
suggesting that the Pik3caRBD allele is functionally recessive
to the Pik3caWT allele. However, our results here (Figure 1C)
showed some difference in overall tumor burden between
Pik3caWT/flox and Pik3caRBD/flox mice. To investigate this further,
we studied tumor formation inmice of the same genotype except
lacking the Rosa26-CreERT2 allele. In this case, we could not
find any significant difference in either tumor number or size,
suggesting that the differences found in our Pik3caWT/flox and
Pik3caRBD/flox mice could be due to some degree of Cre recom-
binase activity in Rosa26-CreERT2 mice even in the absence of
tamoxifen treatment (Figures S1E and S1F).d above.
3caWT/ mice.
phospho-histone H3 staining.
**p < 0.001, ****p < 0.0001). See also Figure S1.
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Figure 2. Expression of p110a-RBD in Established Tumors Reduces Tumor Burden
(A) Schematic representation of mouse treatment and micro-CT scanning intervals.
(B) Ten-week-old mice were left untreated or were treated with tamoxifen for 2 weeks and the effect on tumor volume was assessed by micro-CT analysis over a
6-week period. Tumor volumes are plotted relative to the initial volume at the start of treatment. Black lines represent tumors from Pik3caWT/mice and red lines
represent tumors from Pik3caRBD/ mice. Green lines represent tumors from tamoxifen-treated Pik3caWT/WT mice that express Cre recombinase following
treatment but do not have loxP sites flanking the Pik3ca gene. Pik3caWT/flox n = 4 mice, Pik3caRBD/flox n = 4, Pik3caWT/- n = 6, Pik3caRBD/- n = 4, Pik3caWT/WT
n = 3 mice.
(C) Quantification of TUNEL-positive tumors following tamoxifen treatment for 11 days. Pik3caWT/ n = 5 mice, Pik3caRBD/ n = 7 mice
(legend continued on next page)
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RAS Binding to PI3-Kinase in Tumor MaintenanceRemoval of RAS Interaction with PI3-Kinase p110a in
Established Tumors Induces Partial Tumor Regression
While the previous experiments demonstrate that the interaction
between p110a and RAS plays a critical role in early-stage tumor
development and maintenance, the very small size of lung
tumors in 4-week-old KrasLA2 mice made it impossible to follow
single tumors longitudinally, thus making it hard to distinguish
between changes in tumor development (the appearance of
new tumors) and changes in tumormaintenance (the persistence
of preexisting tumors). We therefore studied the effect of
Pik3caRBD expression in more established tumors in adult
mice. To address this, we treated 10-week-old mice with tamox-
ifen and used micro-computed tomography (micro-CT) analysis
to monitor the growth of individual tumors over a 6-week period
following the start of treatment (Figure 2A). Efficient removal of
the floxed Pik3ca allele was observed soon after treatment and
at the end of the experiment (Figure S2A). We first monitored
tumor growth in the absence of tamoxifen and found that,
while individual tumor growth was variable, both Pik3caWT/flox
and Pik3caRBD/flox tumors consistently increased in volume
over this period (Figure 2B). In contrast, exclusive expression
of Pik3caRBD/ following tamoxifen treatment led to partial
regression of tumors (Figure 2B). Furthermore, to investigate
whether activation of Cre recombinase may by itself have an
impact on tumor growth, mice that had Rosa26-CreERT2 but
no loxP sites flanking Pik3ca were also treated with tamoxifen.
We found that these tumors continued to grow following treat-
ment, and thus the effects observed above are directly depen-
dent on p110a and are not due to Cre recombinase-associated
toxicity (Figures 2B, green lines, and S2B).
As initial tumor regression was evident following tamoxifen
treatment in Pik3caRBD/ mice, we carried out TUNEL staining
on samples generated 10 days after the commencement of
tamoxifen treatment. This revealed that cell death occurred in
many of the mutant tumors following tamoxifen treatment,
although widespread involution of tumors was not evident (Fig-
ure 2C). The effect of mutant expression on tumors was also
evident using histological analysis of lungs (Figures 2D, 2E,
and S2C). The lungs in Pik3caRBD/ mice had fewer tumors pre-
sent and the overall tumor burden in these animals was reduced.
In addition, examination of downstream signaling revealed that
while the level of AKT phosphorylation varied in individual
tumors, mutant tumors displayed lower activation of AKT than
WT tumors (Figure S2D).
Removal of RAS Interaction with PI3-Kinase p110a
Inhibits Tumor Progression
In order to determine the more long-term consequences of
Pik3caRBD expression on tumor development, we followed tumor
growth for 16–32 weeks after tamoxifen treatment (Figure 3A).
Examination of individual tumor growth revealed that while
Pik3caWT/ tumors recovered after the initial tamoxifen treatment
and showed robust tumor expansion over a 4-month period, the(D) Quantification of tumor multiplicity on the pleural surface of lungs. Repres
Pik3caRBD/ mice at 16 weeks of age are shown.
(E) Quantification of tumor burden (tumor area as a percentage of total lung area)
images of histological sections stained with H&E in Pik3caWT/flox, Pik3caRBD/flox,
Error bars indicate mean ± SEM (significance using Student’s t test: *p < 0.05 **
CanPik3caRBD/- tumors remained static and did not progress further
(Figures 3B and S3A). This was particularly clear in the 3D to-
mographs of lungs from treated mice (Figure 3C). Over time,
Pik3caWT/ tumors accumulated in the lungs, with some tumors
merging; however, tumor multiplicity remained low in the
Pik3caRBD/ mice (Figure 3C, right). Interestingly, the tumor bur-
dens in bothPik3caWT/ andPik3caRBD/micewere lower than in
Pik3caWT/flox and Pik3caRBD/flox mice, indicating that some
gene dosage effectsmay be occurring (Figure S3B). Examination
of p110a levels by western blot revealed that a decrease in
p110a expression occurs during tamoxifen treatment, which
may transiently affect growth in Pik3caWT/ tumors (Figure S3C).
Our results demonstrate that in established KrasLA2-driven tu-
mors, the PI3-kinase pathway continues to be an important
mediator of tumor progression. Indeed, at these later time points,
tumor burden was significantly decreased in Pik3caRBD/ mice
versus Pik3caWT/mice and the difference in tumor size became
more evident as the Pik3caWT/ tumors continued to grow (Fig-
ures 3D and S3D). Furthermore, activation of the AKT pathway
downstream of PI3-kinase was impaired in Pik3caRBD/ mice,
indicating that AKT signaling downstream of RAS continues to
be disrupted (Figure 3E). We also utilized standard histological
grading to look at tumor progression (Figure S3E). While overall
tumor number was lower in Pik3caRBD/ mice, the incidence of
higher-grade tumors was also reduced in these mice, with few
grade 3 and no grade 4 adenocarcinomas detected in mutant
mice 16 weeks after treatment (Figure S3F). However, at later
stages of the experiment, some regrowth of mutant tumors
was observed (Figure S3G). Examination of these tumors re-
vealed the presence of unrecombined Pik3ca in mutant tumors.
This indicates that over extended periods of time, a minority of
cells that escaped Cre-mediated recombination during tamox-
ifen treatment may proliferate and restore tumor growth in
Pik3caRBD/ mice (Figure S3G).
We were also interested in the impact of Pik3caRBD expression
on immune cell infiltration into the lungs. To look at this, we
stained lung samples for markers of different immune cell sub-
types. While histological staining showed no dramatic effect of
Pik3caRBD on neutrophils, B cells, or T cells 16 weeks after treat-
ment, we did see a marked decrease in the number of F4/80+
macrophages in the lungs (data not shown; Figure S3H).
Tumor-associated macrophages have been observed previ-
ously in mutant Kras-induced lung tumors in mice and have
broadly been associated with tumor progression (De Palma
and Lewis, 2013; Ji et al., 2006; Pollard, 2004). This suggests
that in addition to direct inhibition of tumor growth, disruption
of RAS signaling to p110a may also affect crosstalk between
the tumor and nontumor host cells.
Tumor Cell-Autonomous Regression on Removal of RAS
Interaction with PI3-Kinase p110a
While the results above indicate a defect in tumor growth and
maintenance in Pik3caRBD/ mice, it is possible that this defectentative images of lungs from Pik3caWT/flox, Pik3caRBD/flox, Pik3caWT/, and
in mice 6 weeks after commencement of tamoxifen treatment. Representative
Pik3caWT/, and Pik3caRBD/ mice at 16 weeks of age are shown.
p < 0.01). See also Figure S2.
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Figure 3. p110a-RBD Mutation Inhibits Tumor Progression
(A) Schematic representation of mouse treatment and micro-CT scanning intervals.
(B) The long-term effect of Pik3caRBD expression on tumor volume was assessed using micro-CT analysis. Lungs were scanned before tamoxifen treatment and
at 3, 9, and 16 weeks after commencement of treatment. Tumor volumes are plotted relative to the initial volume at the start of treatment. Black lines represent
tumors from Pik3caWT/ mice and red lines represent tumors from Pik3caRBD/ mice. Pik3caWT/ n = 3 mice, Pik3caRBD/ n = 3 mice.
(C) Representative tomographs from micro-CT analysis of Pik3caWT/ and Pik3caRBD/ mice before tamoxifen treatment and 16 weeks later. Representative
micro-CT images from each genotype 30 weeks after treatment are shown on the right.
(D) Histological quantification of tumor burden, tumor size, and tumor number either 16 weeks or >32 weeks after the commencement of tamoxifen treatment.
Representative histological images of lungs from Pik3caWT/ and Pik3caRBD/ mice are shown.
(E) Western blot analysis of AKT phosphorylation in tumors extracted from the lungs of Pik3caWT/ and Pik3caRBD/ mice 15 weeks after commencement of
tamoxifen treatment.
Error bars indicate mean ± SEM (significance using Student’s t test: *p < 0.05 **p < 0.01). See also Figure S3.
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RAS Binding to PI3-Kinase in Tumor Maintenanceis not entirely tumor cell autonomous. The Pik3caRBD protein is
present not only in the tumor cells, but also surrounding host
cells, including stromal, endothelial, and immune cells, any of
which could contribute to the observed tumor regression or sta-
sis. In order to investigate this, we derived lung tumor epithelial
cells from 7 to 9 months old KrasLA2Rosa26-CreERT2 mice
that were either Pik3caRBD/flox or Pik3caWT/flox. These animals
had not been exposed to tamoxifen, so the floxed Pik3ca allele
in these cells remained unrecombined. Tumor cells were sorted
to remove immune and endothelial cells and were delivered
intratracheally into the lungs of nude (NuNu) mice. Between 10
and 16 weeks after transplantation, tumors began to be visible
by micro-CT in the lungs of the nude mice, with in all cases
just one tumor detectable per lung. When tumors were visible
by micro-CT, mice were treated with tamoxifen to delete the
floxed Pik3ca allele in the tumor cells and the tumor growth
was followed over a period of 12 weeks. In mice transplanted
with Pik3caWT/flox tumor cells, tumors continued to grow rapidly
after tamoxifen treatment, with a marked decrease in air content
available in the lung (Figures 4A and 4B). However, in mice
bearing Pik3caRBD/flox tumor cells, tumors completely disap-
peared after tamoxifen treatment and had not regrown by the
end of the experiment, with lung air content increasing some-
what over time (Figures 4A and 4B). Furthermore, these effects
led to enhanced survival of mice inoculated with Pik3caRBD/flox
tumor cells versus Pik3caWT/flox tumor cells (Figure 4C).
Histopathology analysis of the lungs of these mice 12 weeks
after tamoxifen treatment showed similar results. NuNu mice
containing Pik3caWT/flox tumor cells had large tumors, generally
just one occupying most of the lobe, although in several of
them there were also small tumor foci in the vicinity of the main
one. All the tumors presented a dominant papillary architecture
and were usually classified as grade 3. Lungs in those mice
explanted with Pik3caRBD/flox cells presented no tumors and
had a normal tissue structure (Figure 4D). These results indicate
a dependence on tumor cell-autonomous RAS interaction with
p110a for tumor maintenance and growth. However, they do
not rule out the possibility that the loss of interaction of RAS
with p110a in host cells might also contribute to the regression
of tumors seen in the autochthonous setting.
Complete Removal of p110a in Established Tumors
Similarly Reduces Tumor Burden
Our experiments thus far have revealed the importance of PI3-
kinase activation by oncogenic Kras for the progression and
continued development of KrasLA2-dependent lung tumors.
While the crucial role of RAS-mediated activation of the PI3-
kinase pathway during initial tumor development has been
clearly demonstrated (Gupta et al., 2007), established tumors
may utilize both internal oncogenic RAS and exogenous growth
factors to activate this important pathway for continued tumor
progression. We were thus interested to investigate whether
complete removal of p110a would provide an additional effect
on tumor growth in comparison to p110a-RBD expression. To
explore this, we treated Pik3caflox/flox mice at 10 weeks of age
with tamoxifen and followed individual tumor growth (Figure 5A).
Tamoxifen treatment resulted in efficient removal of p110a
expression in tumors at the protein level (Figure 5B). In tamox-
ifen-treated Pik3caflox/floxmice, we observed a partial regressionCanof tumors in a manner similar to Pik3caRBD/ expression (Fig-
ure 5C). While the effect of complete removal of p110a expres-
sion was slightly more robust, the change in tumor volume at
the end of the 6-week period was comparable to that seen
with Pik3caRBD/ expression (Figure 5D). Thus, in these tumors
p110a activation appears to be largely dependent upon interac-
tion with RAS.
Histological analysis of Pik3ca/ mice also showed a clear
decrease in the number of tumors present and the overall tumor
burden, while tumor size was not significantly changed (Figures
5E and S4A). Furthermore, ablation of p110a expression in
LKR13 cells established from lung tumors in the KrasLA2 mouse
model resulted in decreased proliferation of these cells (Fig-
ure S4B). This was accompanied by a reduction in downstream
AKT activation. In contrast, ablation of p110b had little effect on
proliferation or AKT signaling, indicating that these cells are pri-
marily dependent on the p110a isoform of PI3-kinase. Analysis of
the long-term effects on tumor growth after tamoxifen treatment
in Pik3caflox/flox mice also demonstrated that tumor progression
was inhibited (Figure 5F). However, regrowth of tumors occurred
more rapidly in these mice than in Pik3caRBD/ mice. Some
residual expression of p110a was found in remaining tumors,
indicating that incomplete recombination in some cells may
allow re-establishment of PI3-kinase signaling and proliferation
in tumors (Figure S4C).
While both p110a-RBD expression and p110a depletion have
a clear effect on oncogenic Kras-driven tumor advancement,
these two genetic alterations may have different effects on
PI3-kinase signaling in nontumorigenic cells. This will be dictated
by the extent of RAS involvement during growth factor-mediated
activation of PI3-kinase signaling. Previous studies exploring the
effect of p110a deletion/blockade on insulin signaling revealed
that this isoform of PI3-kinase is a key mediator of metabolic
responses to insulin (Knight et al., 2006; Sopasakis et al.,
2010). We performed a glucose tolerance test on untreated
mice and tamoxifen-treated Pik3caWT/flox, Pik3caRBD/flox, and
Pik3caflox/flox mice to investigate whether insulin-mediated
removal of glucose from the blood was affected by genetic alter-
ation of Pik3ca. We found that deletion of Pik3ca led to a greater
impairment in glucose removal from the blood, indicating that
nontumorigenic functions of p110a may be affected more by
removal of p110a compared to expression of p110a-RBD
(Figure 5G). Furthermore, the health of Pik3ca/ mice was
more adversely affected than Pik3caRBD/ mice, with signifi-
cantly more mortality occurring within 4 weeks of the start of
treatment (Figure S4D). These results suggest that disruption
of RAS and p110a interaction may target tumor cells more
specifically and may be accompanied by fewer side effects
associated with global inhibition of p110a PI3-kinase function.
Combined PI3-Kinase Pathway Inhibition with MEK
Inhibition Causes Enhanced Tumor Regression
We have found that expression of p110a-RBD caused partial
regression in established tumors, with long-term tumor stasis.
However, with this mutant, we have targeted only one of the
major pathways downstream of RAS, and continued activation
of other pathways may provide sufficient survival signals to
maintain tumor integrity, at least in part. To investigate whether
the ERK/mitogen-activated protein kinase (MAPK) pathwaycer Cell 24, 617–630, November 11, 2013 ª2013 The Authors 623
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Figure 4. Deficient Tumor Growth in p110a-RBD Mutant Mice Is a Cell-Autonomous Process
(A) 3Dmodels showing the growth of transplantedPik3caWT/ andPik3caRBD/ tumor cells in the lung based onmicro-CT images. Due to the tumor occupying the
complete lobe at 12 weeks after treatment in Pik3caWT/ inoculated lungs, modeling was not possible.
Representative images of Pik3caWT/ and Pik3caRBD/ tumor cell inoculated lungs 14 weeks after tamoxifen treatment are shown in the most right panels.
(B)Micewere scanned6and12weeks after tamoxifen treatment. Thegraph represents the normalized air volume in the lungsat themoment of the scanning.Black
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(legend continued on next page)
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Figure 5. Complete Removal of p110a in
Established Tumors Similarly Reduces
Tumor Burden
(A) Schematic representation of mouse treatment
and micro-CT scanning intervals.
(B) Western blot analysis of p110a expression in
tumors extracted from Pik3caflox/flox and Pik3ca/
lungs 3 weeks after commencement of tamoxifen
treatment.
(C) Ten-week-old mice were left untreated or were
treatedwith tamoxifen for 2weeks and the effect on
tumor volume was assessed by micro-CT analysis
over a 6-week period. Black lines represent tumors
from Pik3caflox/flox mice and blue lines represent
tumors from Pik3ca/ mice. Pik3caflox/flox n = 3
animals, Pik3ca/ n = 4 animals.
(D) Change in tumor volume in Pik3caWT/WT,
Pik3caWT/RBD, Pik3caWT/, Pik3caRBD/-, and
Pik3ca/ mice. Ten-week-old mice were left un-
treated or were treated with tamoxifen for 2 weeks
and the effect on tumor volume was assessed by
micro-CT analysis over a 6-week period. Tumor
volumes are plotted relative to the initial volume at
the start of treatment.
(E) Histological quantification of tumor number
and tumor burden in mice 6 weeks after
commencement of tamoxifen treatment. Repre-
sentative images of lungs from Pik3caflox/flox and
Pik3ca/ at 16 weeks of age are also shown.
(F) The long-term effect of Pik3ca removal on
tumor volume was assessed using micro-CT
analysis. Lungs were scanned before tamoxifen
treatment and at various intervals up to 12 weeks
after the commencement of treatment. Black
lines represent tumors from Pik3caflox/flox mice
and blue lines represent tumors from Pik3ca/
mice. Pik3caflox/flox n = 3 animals, Pik3ca/ n = 3
animals.
(G) Glucose tolerance test of Pik3caflox/flox,
Pik3caWT/, Pik3caRBD/, and Pik3ca/ mice
3 weeks after the end of tamoxifen treatment. Mice
were injected with glucose (1 g/kg) and blood
glucose levelsweremeasured at the indicated time
points. Glucose levels are plotted relative to the
initial value before injection. Pik3caflox/flox n = 8
animals,Pik3ca/n=11animals,Pik3caWT/n=6
animals, Pik3caRBD/ n = 8 animals.
Error bars indicate mean ± SEM (significance us-
ing Student’s t test: *p < 0.05). See also Figure S4.
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RAS Binding to PI3-Kinase in Tumor Maintenancewas facilitating the survival of Pik3caRBD;KrasLA2 tumors, we
decided to target this signaling pathway in conjunction with
disruption of PI3-kinase signaling. We treated adult KrasLA2;
Rosa26-CreERT2; Pik3caRBD/flox or KrasLA2;Rosa26-CreERT2;Representative tomographs from micro-CT analysis of Pik3caWT/-derived and Pik3caRBD/-derived tumors
(C) Representation of lifespan of NuNu mice bearing either Pik3caWT/-derived or Pik3caRBD/-derived tu
tumors were sacrificed when the last mouse from the control group had to be culled because of breathing p
(D) Representative images of histological sections stained with H&E in mice inoculated with Pik3caWT/-deriv
after tamoxifen treatment.
Cancer Cell 24, 617–630, NPik3caWT/flox mice with tamoxifen for
2 weeks and then treated with the MEK
inhibitor trametinib for a further 4 weeks,using micro-CT imaging to monitor the effect on tumors. Treat-
ment with trametinib promoted partial tumor regression in
Pik3caWT/ mice, but the effects were significantly stronger in
Pik3caRBD/ mice, with complete regression of some tumorsare shown at the right.
mors. NuNu mice containing Pik3caRBD/-derived
roblems.
ed and Pik3caRBD/-derived tumor cells 14 weeks
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RAS Binding to PI3-Kinase in Tumor Maintenance(Figures 6A, S5A, and S5B). Similar results were found when
mice were treated with the lung cancer chemotherapy combina-
tion carboplatin plus paclitaxel, with Pik3caRBD/mice showing a
stronger response than Pik3caWT/ animals (Figure S5A). We
confirmed that trametinib efficiently inhibited MEK by assessing
the levels of p-ERK in the lungs (Figure S5C). Histological anal-
ysis also revealed a dramatic reduction of tumor burden in these
mice (Figures 6B and S5D). There was a significant decrease in
tumor number as many of the lesions regressed and tumors
that remained were small and dispersed unlike their larger
more compact counterparts in untreated mice (Figure S5E).
Indeed, untreated tumors were consistently higher grade than
those in the combination treatment (Figure S5F). Tumor burden
was also reduced with combined tamoxifen and trametinib treat-
ment of Pik3caWT/flox mice, likely due in some part to the initial
impairment of tumor growth that was observed following
removal of a single allele of Pik3caWT (Figures 2B and S5A).
Next, we aimed to compare these results with pharmacolog-
ical inhibition of PI3-kinase in a similarKras-driven tumorigenesis
background. To do so, we treated KrasLA2 mice with GDC0941,
an orally bioavailable inhibitor of all class I PI3-kinases, BYL719,
a p110a isoform specific inhibitor, and the combination of
GDC0941 or BYL719 and trametinib. We observed a modest
decrease in tumor growth in mice treated with GDC0941 or
BYL719 alone (Figure 6C). Interestingly, treatment of these
mice with GDC0941 or BYL719 alone gave similar tumor re-
sponses, suggesting that the decrease in tumor growth is mainly
achieved by inhibition of p110a isoform. When KrasLA2 mice
were treated with trametinib together with GDC0941, or with
BYL719, a strong tumor regression response was obtained,
with an almost total disappearance of the tumors as evaluated
by micro-CT scanning (Figure 6C). However, the toxicity was
higher in the combined treatments, and treatment had to be
stopped in the final week of the 5-week course in about half of
the mice in these cohorts. The GDC0941 and trametinib combi-
nation tumor regression responsewas significantly stronger than
that obtained with carboplatin plus paclitaxel or GDC0941 com-
binedwith carboplatin plus paclitaxel (Figure S5G). These results
were confirmed in hematoxylin and eosin (H&E) staining where
we could see an almost complete disappearance of the tumors
in lungs from mice treated with the combined trametinib with
GDC0941 or with BYL719 therapy (Figures 6D and S5H–S5J).
Finally, we checked the efficiency of the GDC0941 and trameti-
nib treatments in hitting their targets by assessing p-ERK and
p-AKT levels in tumors of mice treated daily by these drugs.
Both AKT and ERK phosphorylation were inhibited in tumors
treated with their respective pathway inhibitors, either alone or
in combination (Figure S5K).Figure 6. Combined PI3-Kinase Inhibition with MEK Inhibition Induces
(A) Waterfall plot showing tumor response in 10-week-old mice that were treate
trametinib for 4 weeks. Each bar represents one tumor and response is shown r
(B) Representative histological images of lungs frommice, histological quantificat
shown.
(C) KrasLA2 mice were treated with GDC0941 (100 mg/kg/day; green bars), BY
combination of GDC0941 or BYL719 with trametinib (full dose for each drug; red
represents response on tumor growth after 4 weeks treatment. Each bar repres
tamoxifen treatment. Representative images of lungs from mice on each treatme
(D) H&E staining, tumor burden representation, and tumor number assessment f
Error bars indicate mean ± SEM (significance using Student’s t test: *p < 0.05 **
CanDISCUSSION
In these studies, we have attempted to assess the ongoing re-
quirements of preexisting mutant Kras-induced lung tumors for
direct interaction of RAS with p110a and to determine whether
they differ from the previously established almost absolute
requirement for this interaction in the de novo development of
Kras-driven lung tumors (Gupta et al., 2007). We show here
that genetically blocking the interaction of RAS with p110a
causes partial regression of tumors, followed by long-term tumor
stasis, although by itself it is not sufficient to cause complete
regression of established tumors in the autochthonous setting.
This suggests that eradication of existing tumors is harder to
achieve than prevention of the formation of new tumors, with
the requirements for tumor maintenance being less stringent
than for tumor development. However, combination targeting
of RAS’s interaction with p110a with inhibition of the RAF/ERK
pathway at MEK causes much improved tumor regressions.
While RAS-induced activation of PI3-kinase is clearly important
in the continued growth ofRasmutant lung cancer in this system,
we did not see a clear-cut pathway dependency for tumor
maintenance as has been reported by others (Lim and Counter,
2005), but rather contributions of both PI3-kinase and RAF/MEK/
ERK pathways. Although the oncogenic role of RAS in the pro-
motion of lung cancer has been known formany years, treatment
strategies that effectively target RAS mutant tumors have yet to
be established. In contrast to the progress observed with
epidermal growth factor receptor (EGFR) or activin receptor-
like kinase (ALK) inhibitors in lung cancers with alterations
in those driver oncogenes, specific inhibition of RAS mutant
cancers has been difficult to achieve (Maemondo et al., 2010;
Shaw et al., 2013). Our results demonstrate that RAS-induced
PI3-kinase activation is clearly important in these tumors in a
mouse model of Kras-driven lung adenocarcinoma. The PI3-
kinase pathway thus provides an attractive therapeutic target,
with combination of PI3-kinase inhibition with parallel pathway
inhibitors or chemotherapeutic drugs likely to provide the great-
est benefit.
The value of testing the therapeutic response of Kras mutant
lung cancers in mice to the treatment of human disease is clearly
highly dependent on how accurately the genetically engineered
mouse model used reflects human KRAS mutant lung cancer
in the clinic. Several mouse models of Kras-driven lung cancer
have been developed over the past two decades (Kim et al.,
2005). The model that we use in this study, KrasLA2 (Johnson
et al., 2001), is designed to have sporadic expression in single
cells of G12D mutant Kras off its own promoter triggered
by spontaneous intrachromosomal recombination. While theTumor Regression
d with tamoxifen for 2 weeks, left untreated for 5 days, and then treated with
elative to initial tumor volume before tamoxifen treatment.
ions of tumor burden, and tumor number in mice treated as described in (A) are
L719 (50 mg/kg/day; purple bars), trametinib (3 mg/kg/day; blue bars), the
and yellow bars, respectively), or vehicle alone (black bars). The waterfall plot
ents one tumor and response is shown relative to initial tumor volume before
nt are also shown.
rom lungs treated with the drugs described in (C).
p < 0.01, ***p < 0.001, ****p < 0.0001). See also Figure S5.
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RAS Binding to PI3-Kinase in Tumor Maintenancemutant Kras protein is expressed in a few cells in all tissues,
tumor development is seen only in the lung at high penetrance,
with occasional thymic lymphomas also occurring. In another
heavily used model, KrasLSL-G12D (Jackson et al., 2001), expres-
sion of mutant Kras is induced by local introduction of Cre re-
combinase activity in the lung using an adenoviral vector, with
the number of cells expressing mutant Kras being dependent
on the viral titer applied. The KrasLA2 model recapitulates many
of the features of humanKrasmutant lung cancer, and thismodel
has played an important role in extending our knowledge of this
disease (Hatley et al., 2010; Hollander et al., 2011; Takahashi
et al., 2010). Pathological progression of tumors in these mice
from hyperplasia to adenoma and then adenocarcinoma over
time phenocopies the progression of human lung tumors and
permits establishment of a tumor microenvironment in the lungs.
Furthermore, the partial response seen here of lung tumors in
KrasLA2mice to the current standard of care chemotherapies uti-
lized against human lung cancer suggests that this model does
to some degree reflect the therapeutic response of human
Krasmutant lung cancers. Extending the observations described
in our study to more complex Kras/p53 or Kras/Lbk1 mouse
models at a later stage may also provide additional insights
into human KRAS mutant lung cancer biology and treatment.
The earliest point at which Pik3ca gene recombination could
be induced without nonspecific Cre recombinase toxicity was
postweaning, at 4 weeks of age, at which time small lung tumors
are readily detectable in KrasLA2 mice by histology or visual
examination of the lung surface, although not by micro-CT scan-
ning. Although these tumors cannot be followed longitudinally, it
appears that they undergo more profound regressions than
larger tumors treated at 10 weeks. It is possible that larger
tumors acquire additional mechanisms in conjunction with direct
input from RAS for maintaining PI3-kinase pathway activity.
There thus appears to be some evidence for a progressive
decrease in the degree of dependency on direct interaction of
RAS with p110a as tumors become more established.
One concern with the approach used here to study the role of
the RAS binding domain of p110a in vivo is the effect of changing
gene dosage of Pik3ca following Cre recombinase-mediated
deletion of a heterozygous floxed allele. For example, Pik3caRBD
expression and reduction of the WT level may both contribute to
the tumor regression observed in Pik3caRBD/ mice following
tamoxifen treatment. However, this has been controlled for in
all experiments with comparisons made between a single RBD
mutant and a single WT allele of Pik3ca, and we consistently
observed enhanced antitumor effects with Pik3caRBD expres-
sion. When comparison was made between mice in which WT
Pik3ca gene dosage was changed from two to one, some
decrease in tumor growth rate, but never actual tumor regres-
sion, was seen.
In order to distinguish tumor cell-intrinsic requirements for
RAS’s interaction with p110a from effects involving nontumor
cells of the host, such as stroma, endothelial, and immune cells,
we carried out orthotopic transplantation experiments using
tumor cells from engineered mice introduced into the lungs of
animals with normal PI3-kinase signaling. These showed that a
major component of the inhibitory effect of removing the RAS
and p110a interaction on tumor fate could be recapitulated
when the interaction is prevented in the tumor cells alone. We628 Cancer Cell 24, 617–630, November 11, 2013 ª2013 The Authorcannot rule out the possibility that changes in host cell signaling
also contribute, but there is clearly a major tumor cell-autono-
mous effect. The fact that tumor regression occurs in nude
mice indicates that this can occur without the adaptive immune
system, although again it is not possible to exclude a contrib-
uting role. It is also apparent that transplanted tumors actually
show much more profound regressions than autochthonous
tumors when the RAS and p110a interaction is blocked. One
might speculate that the tumor niche established on transplanta-
tion provides a less robustly trophic environment for the tumor
cells than the niche that evolves during the extended evolution
of an autochthonous tumor.
Comparison of the effect on Kras-driven autochthonous
tumors of total deletion of p110a with the removal of the ability
of p110a to interact with RAS reveals similar levels of tumor
regression and stasis. This indicates that in this model of lung
tumors driven by activated Kras, the direct binding of RAS to
p110a is a critical component of the regulation of this PI3-kinase
isoform. However, it is clear that ablating only the RAS interac-
tion with p110a has less systemic toxicity for the mice than total
p110a loss, as exemplified by less disruption of glucose homeo-
stasis and also better general health status. It is noticeable, how-
ever, that ubiquitous loss of p110a in adult mice does not lead
to very major effects on mouse viability when compared with
p110a loss or inactivation in developing embryos (Bi et al.,
1999; Foukas et al., 2006), possibly reflecting some redundancy
between PI3-kinase isoforms, as well as inevitably less than
100% deletion of Pik3ca on Cre activation. It is possible that a
pharmacological strategy that targeted RAS interaction with
p110amay have fewer adverse effects than targeting p110a lipid
kinase activity, but it may still be effective in opposing tumor pro-
gression. Recently, some progress has been made in identifying
small molecules that bind directly to RAS (Maurer et al., 2012;
Shima et al., 2013; Sun et al., 2012), and these might eventually
lead to drugs that would be able to block the interaction of RAS
with downstream effector enzymes. At present, however, the
relatively low potency of the compounds identified, which is
low mM at best, has precluded assessment of their efficacy in
the Kras lung cancer mouse model.
Another likely advantage of direct RAS effector interaction site
targeted drugs would be that they would also be expected to
inhibit other RAS effector pathways such as RAF/MEK/ERK,
which are activated from the same region of RAS. It has long
been clear that inhibition of MEK and PI3-kinase together pro-
motes death of RAS mutant cancer cells (Engelman et al.,
2008), although this approach has significant toxicities and
may not show enhanced selectivity for the RAS mutant pheno-
type relative to cells with wild-type RAS (Molina-Arcas et al.,
2013). Combining pharmacological inhibition of MEK together
with genetic blockade of RAS interaction with p110a also
considerably improved tumor clearance in the model system
used here, as did drug-mediated inhibition of both MEK and
type I PI3-kinases. Use of a p110a isoform-specific PI3-kinase
inhibitor had similar effects to a pan type I PI3-kinase inhibitor,
reinforcing the view that p110a is the critical PI3-kinase isoform
in this setting. We now have evidence that RAS does not control
p110b through direct interaction (Fritsch et al., 2013), so it is
unlikely that inhibition of this ubiquitous isoform will be helpful
in RAS-driven cancer. The other type I PI3-kinase isoforms,s
Cancer Cell
RAS Binding to PI3-Kinase in Tumor Maintenancep110g and p110d, are unlikely to be expressed at major levels in
the epithelial tumor cells studied here, although their inhibition
could play an important role in the interaction of the tumor with
host cells, especially those of the innate and adaptive immune
systems.
Achieving effective targeting of the multiple signaling path-
ways driven by RAS through direct blockade of the effector-
binding region of RAS remains a tantalizing, if distant, goal in
cancer drug discovery. The possibility that drugs might be
made that are specific for mutant, rather than wild-type, RAS
proteins could also add greatly to their therapeutic potential.
The results reported here suggest that such an approach could
show great promise in the treatment of RAS mutant cancers if
the challenge of finding effective RAS-effector protein-protein
interaction inhibitors could be met.
EXPERIMENTAL PROCEDURES
Mouse Model Generation
The final mouse model was generated by breeding of four different mouse
strains: Pik3caRBD (Gupta et al., 2007), KrasLA2 (Johnson et al., 2001),
C57BL/6-Gt(Rosa)26Sortm9(cre/ESR1)Arte (Taconic Artemis Gmbh; referred to
here asRosa26-CreERT2), andPik3caflox/floxmice (Zhao et al., 2006). All animal
experiments were approved by the CRUK London Research Institute Animal
Ethics Committee and conformed with UK Home Office regulations under
The Animals (Scientific Procedures) Act 1986 including Amendment Regula-
tions 2012.
Antibodies
Total ERK, p-ERK (Thr202/Tyr204 -E10) monoclonal, total AKT, pAKT (Ser473),
p-S6, p110a, and p110b antibodies were all purchased from Cell Signaling
Technology. Vinculin antibody was purchased from Sigma. p-PRAS40
(Thr246) was purchased from Invitrogen. For immunohistochemistry, F4/80
antibody was purchased from eBioscience.
Reagents
Tamoxifen diet (400 mg/kg) was obtained from Harlan (Teklad Lab animal
diets). D(+) glucose was obtained from Sigma. Small interfering RNA pools
were obtained from Dharmacon. Trametinib (GSK1120212) and BYL719
were obtained from Active Biochem. GDC0941 and paclitaxel were purchased
from LC Laboratories and Carboplatin from Selleck Chemicals.
In Vivo Tamoxifen and Drug Treatments
Mice were treated with tamoxifen food pellets for 2 weeks and returned to
normal diet for the duration of the experiment. To confirm that Cre-mediated
excision of the floxed allele occurred, DNA was extracted from tumors, lung,
and other tissue samples using Extract-N-Amp Tissue PCR kit (Sigma). Gen-
otyping PCRs for the Pik3ca and Pik3caflox alleles was then carried out using
the following primers: forward 50-CTGTGTAGCCTAGTTTAGAGCAACCAT
CTA-30, reverse 50-CCTCTCTGAACAGTTCATGTTTGATGGTGA-30.
For therapeutic drug treatments, drugs were given by oral gavage daily with
vehicle, trametinib (3 mg/kg/day), GDC0941 (100 mg/kg/day), or BYL719
(50 mg/kg/day) for 5 weeks. Trametinib and GDC0941 were dissolved as
described previously (Gilmartin et al., 2011). Paclitaxel (10mg/kg/day) and car-
boplatin (50 mg/kg/day) were administered by intraperitoneal injections twice
a week, and both drugs were dissolved in PBS.
Histology and Analysis of Tumor Burden
Mice were sacrificed and the lung tissue was immediately removed and fixed
overnight in 10% neutral buffered formalin. The lungs were then transferred to
70% ethanol and processed for paraffin embedding. Tissue sections were cut
at 4 mm and were stained with H&E or were immunostained with various anti-
bodies. Lung and tumor area quantifications were carried out on H&E-stained
slides. Pictures of each lung lobe were taken on a Nikon Eclipse 90i micro-
scope with the 13 objective. Lung and tumor area were measured using NISCanElements 3.0 SP7 software (Nikon Instruments B.V. Europe). Tumor grading
was carried out by a pathologist and tumors were classified according to
standard histopathological grading (Jackson et al., 2005).
Statistical Analysis
Data are presented as mean ± SEM. Significance was determined with
GraphPad Prism 5 software using the Student’s t test unless stated otherwise.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.09.012.
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